Triple-negative breast cancer (TNBC) is aggressive and has the highest rate of metastatic disease and lowest survival rate compared with other breast cancer subtypes. Treatment is challenging due to disease complexity, with available therapies including cytotoxic chemotherapies, PARP inhibitors, immunotherapies, and antibody therapy. There are also disparities to overcome in the treatment of TNBC, as clinical outcomes are impacted by both biologic and nonbiologic factors in various ethnic groups. This activity will explore the clinical data and guideline recommendations for the treatment of TNBC as well as strategies for formulary management. Additionally, panelists will share insights with participants to promote awareness of potential racial disparities in cancer care.
Target Audience: Managed care and oncology pharmacists
Type of Activity: Application
Release date: October 29, 2021
Expiration date: October 29, 2022
Time to complete activity: 1.5 hours
At the completion of this activity, participants will be able to:
• Explore the epidemiology and clinical guideline treatment recommendations for triple-negative breast cancer (TNBC) as well as challenges to care
• Investigate clinical data of new and emerging immunotherapies in the treatment of TNBC
• Analyze the impact of racial disparities on treatment outcomes for patients with TNBC as well as strategies to improve access to care
• Identify strategies for managed care professionals to incorporate TNBC therapies into health-system formularies
Physicians and nurses seeking CE credit are encouraged to register with our partner, Physicians Education Resource (https://www.gotoper.com) and view this activity at https://education.gotoper.com//activity/tnbc21ccatp.